Literature DB >> 25320293

Slaying the Trojan horse: natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and cytolysis against allogeneic T cells.

Shayarana L Gooneratne1, Jonathan Richard2, Wen Shi Lee1, Andrés Finzi2, Stephen J Kent3, Matthew S Parsons4.   

Abstract

UNLABELLED: Many attempts to design prophylactic human immunodeficiency virus type 1 (HIV-1) vaccines have focused on the induction of neutralizing antibodies (Abs) that block infection by free virions. Despite the focus on viral particles, virus-infected cells, which can be found within mucosal secretions, are more infectious than free virus both in vitro and in vivo. Furthermore, assessment of human transmission couples suggests infected seminal lymphocytes might be responsible for a proportion of HIV-1 transmissions. Although vaccines that induce neutralizing Abs are sought, only some broadly neutralizing Abs efficiently block cell-to-cell transmission of HIV-1. As HIV-1 vaccines need to elicit immune responses capable of controlling both free and cell-associated virus, we evaluated the potential of natural killer (NK) cells to respond in an Ab-dependent manner to allogeneic T cells bearing HIV-1 antigens. This study presents data measuring Ab-dependent anti-HIV-1 NK cell responses to primary and transformed allogeneic T-cell targets. We found that NK cells are robustly activated in an anti-HIV-1 Ab-dependent manner against allogeneic targets and that tested target cells are subject to Ab-dependent cytolysis. Furthermore, the educated KIR3DL1(+) NK cell subset from HLA-Bw4(+) individuals exhibits an activation advantage over the KIR3DL1(-) subset that contains both NK cells educated through other receptor/ligand combinations and uneducated NK cells. These results are intriguing and important for understanding the regulation of Ab-dependent NK cell responses and are potentially valuable for designing Ab-dependent therapies and/or vaccines. IMPORTANCE: NK cell-mediated anti-HIV-1 antibody-dependent functions have been associated with protection from infection and disease progression; however, their role in protecting from infection with allogeneic cells infected with HIV-1 is unknown. We found that HIV-1-specific ADCC antibodies bound to allogeneic cells infected with HIV-1 or coated with HIV-1 gp120 were capable of activating NK cells and/or trigging cytolysis of the allogeneic target cells. This suggests ADCC may be able to assist in preventing infection with cell-associated HIV-1. In order to fully utilize NK cell-mediated Ab-dependent effector functions, it might also be important that educated NK cells, which hold the highest activation potential, can become activated against targets bearing HIV-1 antigens and expressing the ligands for self-inhibitory receptors. Here, we show that with Ab-dependent stimulation, NK cells expressing inhibitory receptors can mediate robust activation against targets expressing the ligands for those receptors.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25320293      PMCID: PMC4301139          DOI: 10.1128/JVI.02461-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Authors:  Mattia Bonsignori; Justin Pollara; M Anthony Moody; Michael D Alpert; Xi Chen; Kwan-Ki Hwang; Peter B Gilbert; Ying Huang; Thaddeus C Gurley; Daniel M Kozink; Dawn J Marshall; John F Whitesides; Chun-Yen Tsao; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Georgia D Tomaras; David C Montefiori; George K Lewis; Anthony DeVico; David T Evans; Guido Ferrari; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

Review 2.  Targeting Trojan Horse leukocytes for HIV prevention.

Authors:  Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

3.  Human immunodeficiency virus type 1 Nef induces accumulation of CD4 in early endosomes.

Authors:  O Schwartz; A Dautry-Varsat; B Goud; V Maréchal; A Subtil; J M Heard; O Danos
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

4.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

Authors:  K L Collins; B K Chen; S A Kalams; B D Walker; D Baltimore
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

5.  An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.

Authors:  Guido Ferrari; Justin Pollara; Daniel Kozink; Tiara Harms; Mark Drinker; Stephanie Freel; M Anthony Moody; S Munir Alam; Georgia D Tomaras; Christina Ochsenbauer; John C Kappes; George M Shaw; James A Hoxie; James E Robinson; Barton F Haynes
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

6.  Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding.

Authors:  Adjoa Smalls-Mantey; Nicole Doria-Rose; Rachel Klein; Andy Patamawenu; Stephen A Migueles; Sung-Youl Ko; Claire W Hallahan; Hing Wong; Bai Liu; Lijing You; Johannes Scheid; John C Kappes; Christina Ochsenbauer; Gary J Nabel; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

7.  Efficiency of cell-free and cell-associated virus in mucosal transmission of human immunodeficiency virus type 1 and simian immunodeficiency virus.

Authors:  Dror Kolodkin-Gal; Sandrine L Hulot; Birgit Korioth-Schmitz; Randi B Gombos; Yi Zheng; Joshua Owuor; Michelle A Lifton; Christian Ayeni; Robert M Najarian; Wendy W Yeh; Mohammed Asmal; Gideon Zamir; Norman L Letvin
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

8.  HIV protective KIR3DL1/S1-HLA-B genotypes influence NK cell-mediated inhibition of HIV replication in autologous CD4 targets.

Authors:  Rujun Song; Irene Lisovsky; Bertrand Lebouché; Jean-Pierre Routy; Julie Bruneau; Nicole F Bernard
Journal:  PLoS Pathog       Date:  2014-01-16       Impact factor: 6.823

9.  Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils.

Authors:  Adjoa Smalls-Mantey; Mark Connors; Quentin J Sattentau
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

10.  Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission.

Authors:  Marine Malbec; Françoise Porrot; Rejane Rua; Joshua Horwitz; Florian Klein; Ari Halper-Stromberg; Johannes F Scheid; Caroline Eden; Hugo Mouquet; Michel C Nussenzweig; Olivier Schwartz
Journal:  J Exp Med       Date:  2013-11-25       Impact factor: 14.307

View more
  26 in total

Review 1.  Beyond Viral Neutralization.

Authors:  George K Lewis; Marzena Pazgier; David T Evans; Guido Ferrari; Stylianos Bournazos; Matthew S Parsons; Nicole F Bernard; Andrés Finzi
Journal:  AIDS Res Hum Retroviruses       Date:  2017-02-16       Impact factor: 2.205

2.  Impaired Downregulation of NKG2D Ligands by Nef Proteins from Elite Controllers Sensitizes HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.

Authors:  Nirmin Alsahafi; Jonathan Richard; Jérémie Prévost; Mathieu Coutu; Nathalie Brassard; Matthew S Parsons; Daniel E Kaufmann; Mark Brockman; Andrés Finzi
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

3.  Differential Effect of Mucosal NKp44+ Innate Lymphoid Cells and Δγ Cells on Simian Immunodeficiency Virus Infection Outcome in Rhesus Macaques.

Authors:  Mohammad Arif Rahman; Eun-Ju Ko; Gospel Enyindah-Asonye; Sabrina Helmold Hait; Christopher Hogge; Ruth Hunegnaw; David J Venzon; Tanya Hoang; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2019-09-25       Impact factor: 5.422

Review 4.  Adaptive NK cell responses in HIV/SIV infections: A roadmap to cell-based therapeutics?

Authors:  Daniel R Ram; Cordelia Manickam; Olivier Lucar; Spandan V Shah; R Keith Reeves
Journal:  J Leukoc Biol       Date:  2019-02-07       Impact factor: 4.962

5.  Contribution of NK Cell Education to both Direct and Anti-HIV-1 Antibody-Dependent NK Cell Functions.

Authors:  Anne B Kristensen; Stephen J Kent; Matthew S Parsons
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

Review 6.  Natural killer cells in HIV-1 infection and therapy.

Authors:  Joanna Mikulak; Ferdinando Oriolo; Elisa Zaghi; Clara Di Vito; Domenico Mavilio
Journal:  AIDS       Date:  2017-11-13       Impact factor: 4.177

7.  Potent In Vivo NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein.

Authors:  Ariola Bardhi; Yanling Wu; Weizao Chen; Wei Li; Zhongyu Zhu; Jian Hua Zheng; Hing Wong; Emily Jeng; Jennifer Jones; Christina Ochsenbauer; John C Kappes; Dimiter S Dimitrov; Tianlei Ying; Harris Goldstein
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

8.  Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells.

Authors:  Wen Shi Lee; Jonathan Richard; Marit Lichtfuss; Amos B Smith; Jongwoo Park; Joel R Courter; Bruno N Melillo; Joseph G Sodroski; Daniel E Kaufmann; Andrés Finzi; Matthew S Parsons; Stephen J Kent
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

9.  Functional advantage of educated KIR2DL1(+) natural killer cells for anti-HIV-1 antibody-dependent activation.

Authors:  S L Gooneratne; R J Center; S J Kent; M S Parsons
Journal:  Clin Exp Immunol       Date:  2016-02-04       Impact factor: 4.330

10.  Fc functional antibodies in humans with severe H7N9 and seasonal influenza.

Authors:  Hillary A Vanderven; Lu Liu; Fernanda Ana-Sosa-Batiz; Thi Ho Nguyen; Yanmin Wan; Bruce Wines; P Mark Hogarth; Danielle Tilmanis; Arnold Reynaldi; Matthew S Parsons; Aeron C Hurt; Miles P Davenport; Tom Kotsimbos; Allen C Cheng; Katherine Kedzierska; Xiaoyan Zhang; Jianqing Xu; Stephen J Kent
Journal:  JCI Insight       Date:  2017-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.